_using-parp-inhibitors-to-improve-quality-of-life-for-patients-with-metastatic-breast-cancer.jpg "Using PARP inhibitors to improve quality of life for patients with metastatic breast cancer from parp Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 68 sec
✓ Published: 29-Sep-2019
✓ Published: 29-Sep-2019
Description:
Prof Sherene Loi speaks to ecancer at ESMO 2019 in Barcelona about how PARP inhibitors are currently being used to treat metastatic breast cancer.nnFocusing on patients' quality of life, Prof Loi discusses which PARP inhibitors are currently approved in this setting, how they are currently being used, and with what results.nnSign up to ecancer for free to receive tailored email alerts for more videos like this.necancer.org/account/register.php
Prof Sherene Loi speaks to ecancer at ESMO 2019 in Barcelona about how PARP inhibitors are currently being used to treat metastatic breast cancer.nnFocusing on patients' quality of life, Prof Loi discusses which PARP inhibitors are currently approved in this setting, how they are currently being used, and with what results.nnSign up to ecancer for free to receive tailored email alerts for more videos like this.necancer.org/account/register.php
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_parp-inspiracje-odblaski-124-darek-zatorski.webp "PARP - Inspiracje - Odblaskindir: Darek Zatorskinnprezentacja dorobku - creative showcasenpoint of you")
_part-3-mechanism-of-action-of-parp-inhibitors.webp "Short chapter from the Mechanism of Action of PARP inhibitors and Targeting DNA Damage Response (DDR) video")
_comment-on-solo1-for-advanced-ovarian-cancer.webp "Dr Ledermann speaks with ecancer at ESMO 2018 in Munich about the SOLO1 study of 2 years maintenance olaparib following platinum-based chemotherapy for patients with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation.nnHe emphasises the improved PFS at 3 years with the PARP inhibitor (HR 0.3), with no change in health-related quality of life from standard care.nnThese results were first presented by Dr Kathleen Moore in a conference session.nnecancer's filming has been kindly support")
_too-tall-tina.webp "Cindy Clifford from WALK RADIO 97.5 reads an original story to a fourth grade class at the Riley Avenue School during Parents as Reading Partners Reading Week.")
_prostate-cancer-updates-advances-in-precision-medicine-and-parp-inhibitors.webp "Prof Karim Fizazi (Institut Gustave Roussy, Paris, France) chairs a session with Dr Joaquin Mateo (Vall d’Hebron Institute of Oncology, Barcelona, Spain), Dr Shahneen Sandhu (Peter MacCallum Cancer, Melbourne, Australia) and Prof Bertrand Tombal (Université catholique de Louvain, Brussels, Belgium) on the key developments in prostate cancer that were presented at ESMO 2019. nnProf Tombal provides a summary of the RADICALS trial which investigated the role of radiation therapy in patients with")
⏲ 14 min 47 sec ✓ 02-Oct-2019
_titan-update-on-the-data-and-where-next-for-patients-with-hormone-sensitive-pc.webp "In this expert discussion Prof Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany) and Prof Kim Chi (Vancouver Prostate Centre, Vancouver, Canada) talk about the TITAN study and give updates on the data from it. nnThey also talk about what is next in terms of treatment for patients with hormone sensitive prostate cancer. nnInitially, Prof Chi explains what the TITAN study was about and how it can effect the patients with hormone sensitive prostate cancer. nnProf Merseburg")
⏲ 7 min 84 sec ✓ 15-Feb-2021
_olaparib-continues-to-show-positive-results-in-advanced-ovarian-cancer-7-year-data.webp "Prof Paul DiSilvestro, speaks to ecancer about his Phase III SOLO1/GOG-3004 trial which studied the overall survival at 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation who received maintenance olaparib. nnPatients who were in response to first-line platinum-based chemotherapy received maintenance olaparib tablets 300 mg bid or pbo for up to 2 years or until progression. A descriptive analysis of OS, a secondary endpoint, was performed 7y after the l")
⏲ 2 min 53 sec ✓ 10-Sep-2022
_lschenkel-parp14-aacr-2020.webp "LSchenkel_PARP14 AACR 2020 from parp")
Related Video Searches
Back to Search
Search Videos
Recent Searches
×
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
_parp-inspiracje-odblaski-124-darek-zatorski.jpg)
_part-3-mechanism-of-action-of-parp-inhibitors.jpg)
_comment-on-solo1-for-advanced-ovarian-cancer.jpg)
_too-tall-tina.jpg)
_prostate-cancer-updates-advances-in-precision-medicine-and-parp-inhibitors.jpg)
_titan-update-on-the-data-and-where-next-for-patients-with-hormone-sensitive-pc.jpg)
_olaparib-continues-to-show-positive-results-in-advanced-ovarian-cancer-7-year-data.jpg)
_lschenkel-parp14-aacr-2020.jpg)
❮❯
1 / 10
2 / 10
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
3 / 10
4 / 10
5 / 10
6 / 10
7 / 10
8 / 10
9 / 10
10 / 10
![[+]](/images/menu.gif){kind=small}